Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.

Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A.

Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Review.

2.

Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?

Ottaiano A, Cassata A, Capozzi M, De Divitiis C, De Stefano A, Avallone A.

Front Oncol. 2018 Mar 14;8:62. doi: 10.3389/fonc.2018.00062. eCollection 2018.

3.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2018 Feb;23(2):272. doi: 10.1634/theoncologist.2017-0158erratum. No abstract available.

4.

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.

Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F.

PLoS One. 2018 Jan 19;13(1):e0191593. doi: 10.1371/journal.pone.0191593. eCollection 2018.

5.

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.

Terranova-Barberio M, Pecori B, Roca MS, Imbimbo S, Bruzzese F, Leone A, Muto P, Delrio P, Avallone A, Budillon A, Di Gennaro E.

J Exp Clin Cancer Res. 2017 Dec 6;36(1):177. doi: 10.1186/s13046-017-0647-5.

6.

Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy.

Ottaiano A, Napolitano M, Capozzi M, Tafuto S, Avallone A, Scala S.

World J Clin Cases. 2017 Nov 16;5(11):390-396. doi: 10.12998/wjcc.v5.i11.390.

7.

MR imaging perfusion and diffusion analysis to assess preoperative Short Course Radiotherapy response in locally advanced rectal cancer: Standardized Index of Shape by DCE-MRI and intravoxel incoherent motion-derived parameters by DW-MRI.

Petrillo A, Fusco R, Granata V, Setola SV, Sansone M, Rega D, Delrio P, Bianco F, Romano GM, Tatangelo F, Avallone A, Pecori B.

Med Oncol. 2017 Nov 18;34(12):198. doi: 10.1007/s12032-017-1059-2.

PMID:
29151142
8.

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G.

Future Oncol. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4. Erratum in: Future Oncol. 2018 Mar;14 (6):577.

PMID:
28976226
9.

Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows.

Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, Grassi R, Izzo F, Petrillo A.

Oncotarget. 2017 Apr 19;8(31):51224-51237. doi: 10.18632/oncotarget.17227. eCollection 2017 Aug 1.

10.

Near-source high-rate GPS, strong motion and InSAR observations to image the 2015 Lefkada (Greece) Earthquake rupture history.

Avallone A, Cirella A, Cheloni D, Tolomei C, Theodoulidis N, Piatanesi A, Briole P, Ganas A.

Sci Rep. 2017 Sep 4;7(1):10358. doi: 10.1038/s41598-017-10431-w.

11.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2017 Dec;22(12):1463-1469. doi: 10.1634/theoncologist.2017-0158. Epub 2017 Aug 31. Erratum in: Oncologist. 2018 Feb;23 (2):272.

PMID:
28860412
12.

FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.

Ottaiano A, Nasti G, Cassata A, De Stefano A, Caraglia M, Avallone A.

Cancer Lett. 2017 Nov 1;408:71-72. doi: 10.1016/j.canlet.2017.08.025. Epub 2017 Aug 24. No abstract available.

PMID:
28844712
13.

Uncommon neoplasms of the biliary tract: radiological findings.

Granata V, Fusco R Md, Catalano O, Filice S, Avallone A, Piccirillo M, Leongito M, Palaia R, Grassi R, Izzo F, Petrillo A.

Br J Radiol. 2017 Oct;90(1078):20160561. doi: 10.1259/bjr.20160561. Epub 2017 Jul 21.

PMID:
28731820
14.

Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.

Granata V, Fusco R, Catalano O, Avallone A, Palaia R, Botti G, Tatangelo F, Granata F, Cascella M, Izzo F, Petrillo A.

PLoS One. 2017 Jun 20;12(6):e0179951. doi: 10.1371/journal.pone.0179951. eCollection 2017.

15.

Peribiliary liver metastases MR findings.

Granata V, Fusco R, Catalano O, Avallone A, Leongito M, Izzo F, Petrillo A.

Med Oncol. 2017 Jul;34(7):124. doi: 10.1007/s12032-017-0981-7. Epub 2017 Jun 1.

PMID:
28573638
16.

Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update.

Granata V, Fusco R, Avallone A, Catalano O, Filice F, Leongito M, Palaia R, Izzo F, Petrillo A.

Infect Agent Cancer. 2017 Apr 28;12:23. doi: 10.1186/s13027-017-0132-y. eCollection 2017. Review.

17.

Aseismic transient during the 2010-2014 seismic swarm: evidence for longer recurrence of M ≥ 6.5 earthquakes in the Pollino gap (Southern Italy)?

Cheloni D, D'Agostino N, Selvaggi G, Avallone A, Fornaro G, Giuliani R, Reale D, Sansosti E, Tizzani P.

Sci Rep. 2017 Apr 12;7(1):576. doi: 10.1038/s41598-017-00649-z.

18.

Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.

Ottaiano A, Capozzi M, DE Divitiis C, VON Arx C, DI Girolamo E, Nasti G, Cavalcanti E, Tatangelo F, Romano G, Avallone A, Tafuto S.

Anticancer Res. 2017 Apr;37(4):1975-1978.

PMID:
28373469
19.

Obesity and Cancer: Biological Links and Treatment Implications.

Ottaiano A, De Divitiis C, Capozzi M, Avallone A, Pisano C, Pignata S, Tafuto S.

Curr Cancer Drug Targets. 2018;18(3):231-238. doi: 10.2174/1568009617666170330125619.

PMID:
28359241
20.

Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.

Ottaiano A, Capozzi M, De Divitiis C, De Stefano A, Botti G, Avallone A, Tafuto S.

Acta Oncol. 2017 Mar;56(3):377-383. doi: 10.1080/0284186X.2017.1288922. Epub 2017 Feb 17. Review.

PMID:
28256961
21.

T1 colon cancer in the era of screening: risk factors and treatment.

Bianco F, De Franciscis S, Belli A, Falato A, Fusco R, Altomare DF, Amato A, Asteria CR, Avallone A, Binda GA, Boccia L, Buzzo P, Carvello M, Coco C, Delrio P, De Nardi P, Di Lena M, Failla A, La Torre F, La Torre M, Lemma M, Luffarelli P, Manca G, Maretto I, Marino F, Muratore A, Pascariello A, Pucciarelli S, Rega D, Ripetti V, Rizzo G, Serventi A, Spinelli A, Tatangelo F, Urso ED, Romano GM; Italian Society of Colo-Rectal Surgery (SICCR) Cancer Group.

Tech Coloproctol. 2017 Feb;21(2):139-147. doi: 10.1007/s10151-017-1586-z. Epub 2017 Feb 13.

PMID:
28194568
22.

Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis.

Pecori B, Lastoria S, Caracò C, Celentani M, Tatangelo F, Avallone A, Rega D, De Palma G, Mormile M, Budillon A, Muto P, Bianco F, Aloj L, Petrillo A, Delrio P.

PLoS One. 2017 Jan 6;12(1):e0169462. doi: 10.1371/journal.pone.0169462. eCollection 2017.

23.

Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile.

Petrillo A, Fusco R, Petrillo M, Granata V, Delrio P, Bianco F, Pecori B, Botti G, Tatangelo F, Caracò C, Aloj L, Avallone A, Lastoria S.

Oncotarget. 2017 Jan 31;8(5):8143-8153. doi: 10.18632/oncotarget.14106.

24.

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G.

Gastric Cancer. 2017 Sep;20(5):825-833. doi: 10.1007/s10120-016-0681-6. Epub 2016 Dec 27.

PMID:
28028664
25.

Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for Hepatocellular carcinoma: correlation with histologic grade.

Granata V, Fusco R, Catalano O, Guarino B, Granata F, Tatangelo F, Avallone A, Piccirillo M, Palaia R, Izzo F, Petrillo A.

Oncotarget. 2016 Nov 29;7(48):79357-79364. doi: 10.18632/oncotarget.12689.

26.

Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer.

Rega D, Pecori B, Scala D, Avallone A, Pace U, Petrillo A, Aloj L, Tatangelo F, Delrio P.

PLoS One. 2016 Aug 22;11(8):e0160732. doi: 10.1371/journal.pone.0160732. eCollection 2016.

27.

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.

Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G, Giuliani F, Bordonaro R, Scartozzi M, De Maglio G, Negri FV, Fasola G, Aprile G.

Oncotarget. 2016 Oct 18;7(42):69060-69074. doi: 10.18632/oncotarget.11264. Review.

28.

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial.

Avallone A, Budillon A.

J Clin Oncol. 2016 May 1;34(13):1564. doi: 10.1200/JCO.2015.66.1512. Epub 2016 Mar 7. No abstract available.

PMID:
26951321
29.

A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer.

Rosati G, Aprile G, Cardellino GG, Avallone A.

J Geriatr Oncol. 2016 Mar;7(2):134-41. doi: 10.1016/j.jgo.2016.01.006. Epub 2016 Feb 18. Review.

PMID:
26897044
30.

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).

Avallone A, Piccirillo MC, Aloj L, Nasti G, Delrio P, Izzo F, Di Gennaro E, Tatangelo F, Granata V, Cavalcanti E, Maiolino P, Bianco F, Aprea P, De Bellis M, Pecori B, Rosati G, Carlomagno C, Bertolini A, Gallo C, Romano C, Leone A, Caracò C, de Lutio di Castelguidone E, Daniele G, Catalano O, Botti G, Petrillo A, Romano GM, Iaffaioli VR, Lastoria S, Perrone F, Budillon A.

BMC Cancer. 2016 Feb 8;16:69. doi: 10.1186/s12885-016-2102-y.

31.

Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.

Trotta AM, Ottaiano A, Romano C, Nasti G, Nappi A, De Divitiis C, Napolitano M, Zanotta S, Casaretti R, D'Alterio C, Avallone A, Califano D, Iaffaioli RV, Scala S.

Cancer Immunol Res. 2016 Apr;4(4):366-74. doi: 10.1158/2326-6066.CIR-15-0184. Epub 2016 Jan 27.

32.

Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy.

Ottaiano A, Nappi A, Tafuto S, Nasti G, De Divitiis C, Romano C, Cassata A, Casaretti R, Silvestro L, Avallone A, Capuozzo M, Capozzi M, Maiolino P, Quagliariello V, Scala S, Iaffaioli VR.

Oncology. 2016;90(1):36-42. doi: 10.1159/000442527. Epub 2016 Jan 6.

PMID:
26731722
33.

Surgery has a key role for quality assurance of colorectal cancer screening programs: impact of the third level multidisciplinary team on lymph nodal staging.

Bianco F, De Franciscis S, Belli A, Di Lena M, Avallone A, Bianco MA, Di Marzo S, Gigli L, Rotondano G, Spena SR, Tatangelo F, Tempesta A, Romano GM.

Int J Colorectal Dis. 2016 Mar;31(3):587-92. doi: 10.1007/s00384-015-2472-7. Epub 2015 Dec 29.

PMID:
26715436
34.

Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.

Granata V, Fusco R, Catalano O, Filice S, Amato DM, Nasti G, Avallone A, Izzo F, Petrillo A.

PLoS One. 2015 Nov 13;10(11):e0142876. doi: 10.1371/journal.pone.0142876. eCollection 2015.

35.

MRI for Assessing Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer Using DCE-MR and DW-MR Data Sets: A Preliminary Report.

Petrillo M, Fusco R, Catalano O, Sansone M, Avallone A, Delrio P, Pecori B, Tatangelo F, Petrillo A.

Biomed Res Int. 2015;2015:514740. doi: 10.1155/2015/514740. Epub 2015 Aug 27.

36.

Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.

Avallone A, Pecori B, Bianco F, Aloj L, Tatangelo F, Romano C, Granata V, Marone P, Leone A, Botti G, Petrillo A, Caracò C, Iaffaioli VR, Muto P, Romano G, Comella P, Budillon A, Delrio P.

Oncotarget. 2015 Oct 6;6(30):30394-407. doi: 10.18632/oncotarget.4724.

37.

Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.

Aprile G, Fontanella C, Bonotto M, Rihawi K, Lutrino SE, Ferrari L, Casagrande M, Ongaro E, Berretta M, Avallone A, Rosati G, Giuliani F, Fasola G.

Oncotarget. 2015 Oct 6;6(30):28716-30. doi: 10.18632/oncotarget.4747. Review.

38.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827b. No abstract available.

PMID:
26151329
39.

The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA "uptake" on the hepatobiliary phase of MR imaging.

Granata V, Catalano O, Fusco R, Tatangelo F, Rega D, Nasti G, Avallone A, Piccirillo M, Izzo F, Petrillo A.

Abdom Imaging. 2015 Oct;40(7):2364-71. doi: 10.1007/s00261-015-0488-7.

PMID:
26105523
40.

A perspective on the current treatment strategies for locally advanced rectal cancer.

Avallone A, Aloj L, Aprile G, Rosati G, Budillon A.

Int J Biochem Cell Biol. 2015 Aug;65:192-6. doi: 10.1016/j.biocel.2015.06.002. Epub 2015 Jun 6. Review.

PMID:
26055517
41.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Erratum in: Nat Med. 2015 Jul;21(7):doi:10.1038/nm0715-827b. Nat Med. 2015 Jul;21(7):827.

42.

Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study.

Lutrino SE, Bergamo F, Schirripa M, Rosati G, Avallone A, Giampieri R, Cordio S, Berretta M, Llimpe FR, Pisa FE, Lonardi S, Loupakis F, Fasola G, Aprile G.

Anticancer Res. 2015 Apr;35(4):2391-9.

PMID:
25862905
43.

Standardized Index of Shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC.

Petrillo A, Fusco R, Petrillo M, Granata V, Sansone M, Avallone A, Delrio P, Pecori B, Tatangelo F, Ciliberto G.

Eur Radiol. 2015 Jul;25(7):1935-45. doi: 10.1007/s00330-014-3581-3. Epub 2015 Jan 11.

PMID:
25577525
44.

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A.

BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875.

45.

A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.

D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S.

Int J Cancer. 2014 Jul 15;135(2):379-90. doi: 10.1002/ijc.28689. Epub 2014 Jan 10.

46.

New perspective for an old antidiabetic drug: metformin as anticancer agent.

Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A.

Cancer Treat Res. 2014;159:355-76. doi: 10.1007/978-3-642-38007-5_21. Review.

PMID:
24114491
47.

Gastrointestinal non colorectal cancer. Do elderly patients need a specific management?

Silvestro L, Nasti G, Ottaiano A, Montano M, Casaretti R, Avallone A, Berretta M, Romano C, Cassata A, Tafuto S, Iaffaioli RV.

Anticancer Agents Med Chem. 2013 Nov;13(9):1364-70. Review.

PMID:
24102272
48.

Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.

Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A.

Expert Opin Drug Saf. 2014 Jan;13(1):113-29. doi: 10.1517/14740338.2014.845167. Epub 2013 Oct 5. Review.

PMID:
24093908
49.

Multidisciplinary approach to rectal cancer: are we ready for selective treatment strategies?

Avallone A, Aloj L, Delrio P, Pecori B, Leone A, Tatangelo F, Perri F, Petrillo A, Scott N, Budillon A.

Anticancer Agents Med Chem. 2013 Jul 1;13(6):852-60.

PMID:
23272969
50.

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.

Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D.

Cancer Chemother Pharmacol. 2013 Jan;71(1):257-64. doi: 10.1007/s00280-012-2004-x. Epub 2012 Oct 26.

PMID:
23100174

Supplemental Content

Loading ...
Support Center